Search

Your search keyword '"Jane Ruppel"' showing total 2 results
Start Over Author "Jane Ruppel" Publisher bmj publishing group
2 results on '"Jane Ruppel"'

1. Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer

Author

Colby S. Shemesh, Pascal Chanu, Kris Jamsen, Russ Wada, Gianluca Rossato, Francis Donaldson, Amit Garg, Helen Winter, Jane Ruppel, Xin Wang, Rene Bruno, Jin Jin, and Sandhya Girish

Subjects
Atezolizumab, Cancer immunotherapy, Clinical pharmacology, Exposure-safety, Immune checkpoint inhibitor, Pediatric oncology, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background The iMATRIX-atezolizumab study was a phase I/II, multicenter, open-label study designed to assess the safety and pharmacokinetics of atezolizumab in pediatric and young adult patients. We describe the pharmacokinetics (PK), exposure-safety, and immunogenicity of atezolizumab in pediatric and young adults with metastatic solid tumors or hematologic malignancies enrolled in this study. Methods Patients aged

Published
2019
Full Text
View/download PDF

2. Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer

Author

Russ Wada, Kris M. Jamsen, Sandhya Girish, Colby S. Shemesh, Helen Winter, Xin Wang, Jane Ruppel, Gianluca Rossato, Rene Bruno, Pascal Chanu, Francis Donaldson, Amit Garg, and Jin Jin

Subjects
0301 basic medicine, Male, Cancer Research, Cancer immunotherapy, Pediatric oncology, Immune checkpoint inhibitor, law.invention, 0302 clinical medicine, law, Neoplasms, Immunology and Allergy, Population pharmacokinetics, Young adult, Atezolizumab, Child, Volume of distribution, Clinical pharmacology, Immunogenicity, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Progression-Free Survival, Treatment Outcome, Exposure-safety, Oncology, 030220 oncology & carcinogenesis, Child, Preschool, Molecular Medicine, Female, Research Article, Adult, medicine.medical_specialty, Adolescent, Immunology, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, Models, Biological, lcsh:RC254-282, 03 medical and health sciences, Young Adult, Pharmacokinetics, Internal medicine, medicine, Humans, Dosing, Pharmacology, business.industry, Cancer, Infant, medicine.disease, 030104 developmental biology, business
Abstract

Background The iMATRIX-atezolizumab study was a phase I/II, multicenter, open-label study designed to assess the safety and pharmacokinetics of atezolizumab in pediatric and young adult patients. We describe the pharmacokinetics (PK), exposure-safety, and immunogenicity of atezolizumab in pediatric and young adults with metastatic solid tumors or hematologic malignancies enrolled in this study. Methods Patients aged

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results